{
  "source": "PA-Notification-Augtyro.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 1430-2\nProgram Prior Authorization/Notification\nMedication Augtyro™ (repotrectinib)\nP&T Approval Date 1/2024, 8/2024\nEffective Date 11/1/2024\n1. Background:\nAugtyro (repotrectinib) is a kinase inhibitor indicated for the treatment of adult patients with\nlocally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Augtyro\nis also indicated for the treatment of adult and pediatric patients 12 years of age and older\nwith solid tumors that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are\nlocally advanced or metastatic or where surgical resection is likely to result in severe\nmorbidity, and have progressed following treatment or have no satisfactory alternative\ntherapy. This indication is approved under accelerated approval based on overall response\nrate and duration of response. Continued approval for this indication may be contingent upon\nverification and description of clinical benefit in the confirmatory trials.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the\nage of 19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Augtyro will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Non-small cell lung cancer (NSCLC)\n1. Initial Authorization\na. Augtyro will be approved based on all of the following criteria:\n(1) Diagnosis of non-small cell lung cancer (NSCLC)\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\n(2) Disease is one of the following:\n",
    "ugtyro will be approved based on all of the following criteria:\n(1) Diagnosis of non-small cell lung cancer (NSCLC)\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\n(2) Disease is one of the following:\n(a) Advanced\n(b) Metastatic\n-AND-\n(3) Disease is ROS1-positive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Augtyro will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Augtyro therapy\nAuthorization will be issued for 12 months.\nC. Solid Tumors\n1. Initial Authorization\na. Augtyro will be approved based on all of the following criteria:\n(1) Presence of solid tumor(s)\n-AND-\n(2) Disease is positive for neurotrophic tyrosine receptor kinase (NTRK) gene\nfusion (e.g., ETV6-NTRK3, TPM3-NTRK1, LMNA-NTRK1, etc.)\n-AND-\n(3) Disease is one of the following:\n(a) Locally advanced\n(b) Metastatic\n(c) Unresectable\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Augtyro will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Augtyro therapy\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B.\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply",
    "based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Augtyro [package insert]. Bristol-Myers Squibb Company: Princeton, NJ; June 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed July\n5, 2024.\nProgram Prior Authorization/Notification - Augtyro (repotrectinib)\nChange Control\n1/2024 New program.\n8/2024 Updated background and coverage criteria to include new indication for\nsolid tumors with NTRK gene fusion per package insert. Updated\nreferences.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}